{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:11:51Z","timestamp":1788783111388,"version":"build-2803163510"},"reference-count":45,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China (973 Program)","doi-asserted-by":"crossref","award":["2020YFE0201700"],"award-info":[{"award-number":["2020YFE0201700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Frontier Technology Platform Program of Educational Department of Liaoning Province","award":["LJ232410163022"],"award-info":[{"award-number":["LJ232410163022"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (NSFC)","doi-asserted-by":"crossref","award":["82172086"],"award-info":[{"award-number":["82172086"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cabazitaxel (CTX) exhibits potent antineoplastic activity and is demonstrated to promote antitumor immunity by triggering immunogenic cell death (ICD). This is commonly used in the clinical treatment of advanced and metastatic triple-negative breast cancer (TNBC). However, the therapeutic index of commercial CTX injections is severely restricted by their definite systemic toxicity and low tolerability. Herein, we developed biomimetic low-density lipoprotein nanoparticles (CTX2TK&amp;VP@LDL NPs) by integrating ROS-responsive CTX dimeric prodrugs (CTX2TK) and the photosensitizer verteporfin (VP) into LDL NPs to selectively target tumors and achieve synergistic chemophotodynamic therapy and immunotherapy for TNBC with improved biosafety. CTX2TK&amp;VP@LDL NPs were able to enhance the accumulation and cellular uptake in 4T1 tumors overexpressing LDL receptor, improving the targeted codelivery efficiency. When CTX2TK&amp;VP@LDL NPs were deposited at the tumor sites, localized 1O2 was generated upon irradiation for triggering ultrafast CTX release with low premature CTX leakage in the off-target tissue. Additionally, the generated 1O2 can further synergistically reinforce ICD and elicit robust antitumor immune activation. The combination treatment with CTX2TK&amp;VP@LDL NPs and PD-L1 blockade notably inhibited abscopal tumor growth and lung metastasis. Taken together, the biomimetic CTX2TK&amp;VP@LDL NPs exploit endogenous LDL functionality to enable receptor-mediated tumor targeting and synergistic chemophotodynamic immune activation, providing an effective and safe therapeutic strategy for TNBC.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00317","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:12:15Z","timestamp":1785849135000},"page":"4579-4595","source":"Crossref","is-referenced-by-count":0,"title":["Low-Density\nLipoprotein-Mimetic Nanoparticles Codelivering\nSelf-Activated Cabazitaxel Prodrug and Verteporfin for Tumor Chemophotodynamic\nTherapy and Immune Activation"],"prefix":"10.1021","volume":"23","author":[{"given":"Mingli","family":"Wei","sequence":"first","affiliation":[{"name":"Shenyang Pharmaceutical University , , , ,","place":["Shenyang, Liaoning, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxiao","family":"Chu","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , , ,","place":["Shenyang, Liaoning, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiwei","family":"Ding","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , ,","place":["Shenyang, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiansong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , , ,","place":["Shenyang, Liaoning, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muse","family":"Ji","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , , ,","place":["Shenyang, Liaoning, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Liang","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , , ,","place":["Shenyang, Liaoning, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshuang","family":"Bi","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , , ,","place":["Shenyang, Liaoning, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , , ,","place":["Shenyang, Liaoning, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Gou","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , , ,","place":["Shenyang, Liaoning, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Yin","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , , ,","place":["Shenyang, Liaoning, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4154-2159","authenticated-orcid":true,"given":"Haibing","family":"He","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , , ,","place":["Shenyang, Liaoning, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5313-9901","authenticated-orcid":true,"given":"Xing","family":"Tang","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , , ,","place":["Shenyang, Liaoning, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shenyang University , , ,","place":["Shenyang, China, 110044"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0978-2363","authenticated-orcid":true,"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shenyang Pharmaceutical University , , , ,","place":["Shenyang, Liaoning, China, 110016"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"2026090707083559800_cit1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","article-title":"Pathogenesis of Triple-Negative Breast Cancer","volume":"17","author":"Derakhshan","year":"2022","journal-title":"Annu. Rev. Pathol.:Mech. Dis."},{"key":"2026090707083559800_cit2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into\nmolecular classifications\nof triple-negative breast cancer: Improving patient selection for\ntreatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discovery"},{"key":"2026090707083559800_cit3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.17305\/bjbms.2019.4204","article-title":"Targeted immunotherapy\nwith a checkpoint inhibitor in combination with chemotherapy: A new\nclinical paradigm in the treatment of triple-negative breast cancer","volume":"19","author":"Cyprian","year":"2019","journal-title":"Bosnian J. Basic Med. Sci."},{"key":"2026090707083559800_cit4","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1158\/1078-0432.CCR-19-3545","article-title":"FDA\napproval summary:\nAtezolizumab plus paclitaxel protein-bound for the treatment of patients\nwith advanced or metastatic TNBC whose tumors express PD-L1","volume":"26","author":"Narayan","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"2026090707083559800_cit5","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"WG. Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol. Oncol."},{"key":"2026090707083559800_cit6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death:\nRecommendations of the Nomenclature Committee on Cell Death","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death Differ."},{"key":"2026090707083559800_cit7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122433","article-title":"Genetically\nlight-enhanced immunotherapy mediated by a fluorinated\nreduction-sensitive delivery system","volume":"305","author":"Su","year":"2024","journal-title":"Biomaterials"},{"key":"2026090707083559800_cit8","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202201401","article-title":"Radiation-induced immunogenic\ncell death for cancer radioimmunotherapy","volume":"7","author":"Liu","year":"2023","journal-title":"Small\nMethods"},{"key":"2026090707083559800_cit9","doi-asserted-by":"publisher","first-page":"12087","DOI":"10.1039\/D1CC04604G","article-title":"Immunogenic\ncell death inducers for enhanced cancer immunotherapy","volume":"57","author":"Li","year":"2021","journal-title":"Chem. Commun."},{"key":"2026090707083559800_cit10","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.apsb.2023.12.001","article-title":"A pH\/ROS dual-responsive system for effective chemoimmunotherapy\nagainst melanoma via remodeling tumor immune microenvironment","volume":"14","author":"Wang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"2026090707083559800_cit11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pscia.2024.100041","article-title":"Rational design of\nsiRNA-based delivery\nsystems for effective treatment of brain diseases","volume":"2","author":"Lu","year":"2024","journal-title":"Pharm. Sci. Adv."},{"key":"2026090707083559800_cit12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pscia.2024.100046","article-title":"Dual-targeting liposomal\ndelivery of sorafenib and\ndocetaxel for enhanced synergistic therapy in advanced hepatocellular\ncarcinoma","volume":"2","author":"Yao","year":"2024","journal-title":"Pharm. Sci. Adv."},{"key":"2026090707083559800_cit13","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.apsb.2022.06.008","article-title":"Photosensitive\npro-drug nanoassemblies harboring a\nchemotherapeutic dormancy function potentiates cancer immunotherapy","volume":"13","author":"Cheng","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"2026090707083559800_cit14","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202214824","article-title":"A NIR-II\nfluorescent PolyBodipy delivering cationic Pt-NHC with type II immunogenic\ncell death for combined chemotherapy and photodynamic immunotherapy","volume":"33","author":"Wang","year":"2023","journal-title":"Adv. Funct. Mater."},{"key":"2026090707083559800_cit15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pscia.2023.100009","article-title":"Blockage of HSP90 and\nIDO1 pathway by \u03b1-MSH modified nanoelicitor to dual-facilitate\nmild photothermal therapy","volume":"1","author":"Fu","year":"2023","journal-title":"Pharm. Sci. Adv."},{"key":"2026090707083559800_cit16","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1158\/1078-0432.CCR-12-3146","article-title":"Preclinical antitumor activity of cabazitaxel, a semisynthetic\ntaxane active in taxane-resistant tumors","volume":"19","author":"Vrignaud","year":"2013","journal-title":"Clin.\nCancer Res."},{"key":"2026090707083559800_cit17","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.bioactmat.2020.11.016","article-title":"Immunogenic-cell-killing and immunosuppression-inhibiting nanomedicine","volume":"6","author":"Wang","year":"2021","journal-title":"Bioact. Mater."},{"key":"2026090707083559800_cit18","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202102043","article-title":"Overcoming\nchemoimmunotherapy-induced immunosuppression\nby assemblable and depot forming immune modulating nanosuspension","volume":"8","author":"Jin","year":"2021","journal-title":"Adv. Sci."},{"key":"2026090707083559800_cit19","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/ijc.29231","article-title":"CAST: A retrospective\nanalysis of cabazitaxel and abiraterone acetate sequential treatment\nin patients with metastatic castrate-resistant prostate cancer previously\ntreated with docetaxel","volume":"136","author":"Wissing","year":"2015","journal-title":"Int. J. Cancer"},{"key":"2026090707083559800_cit20","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1016\/j.apsb.2022.06.016","article-title":"Tumor-microenvironment activated duplex genome-editing nanoprodrug\nfor sensitized near-infrared titania phototherapy","volume":"12","author":"Li","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"2026090707083559800_cit21","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202001853","article-title":"Polymeric Nanoparticles with ROS-Responsive Prodrug\nand Platinum Nanozyme for Enhanced Chemophotodynamic Therapy of Colon\nCancer","volume":"7","author":"Hao","year":"2020","journal-title":"Adv. Sci."},{"key":"2026090707083559800_cit22","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202201819","article-title":"Targeting Bone Tumor and Subcellular Endoplasmic Reticulum via Near\nInfrared II Fluorescent Polymer for Photodynamic-Immunotherapy to\nBreak the Step-Reduction Delivery Dilemma","volume":"9","author":"Zhang","year":"2022","journal-title":"Adv.\nSci."},{"key":"2026090707083559800_cit23","doi-asserted-by":"publisher","first-page":"19468","DOI":"10.1021\/acsnano.1c06225","article-title":"A Facile Low-Dose Photosensitizer-Incorporated\nDissolving\nMicroneedles-Based Composite System for Eliciting Antitumor Immunity\nand the Abscopal Effect","volume":"15","author":"Bian","year":"2021","journal-title":"ACS Nano"},{"key":"2026090707083559800_cit24","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1021\/ar200017e","article-title":"Lipoprotein-Inspired\nNanoparticles\nfor Cancer Theranostics","volume":"44","author":"Ng","year":"2011","journal-title":"Acc. Chem. Res."},{"key":"2026090707083559800_cit25","doi-asserted-by":"publisher","first-page":"10399","DOI":"10.1002\/anie.201704674","article-title":"Reconstitution of Low-Density\nLipoproteins with Fatty\nAcids for the Targeted Delivery of Drugs into Cancer Cells","volume":"56","author":"Zhu","year":"2017","journal-title":"Angew. Chem., Int. Ed."},{"key":"2026090707083559800_cit26","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.actbio.2019.06.051","article-title":"Low Density Lipoprotein-Inspired Nanostructured Lipid Nanoparticles\nContaining Pro-Doxorubicin to Enhance Tumor-Targeted Therapeutic Efficiency","volume":"96","author":"Li","year":"2019","journal-title":"Acta Biomater."},{"key":"2026090707083559800_cit27","first-page":"73","article-title":"Targeting\nof Tumor Cells by Low Density Lipoproteins: Principle and Use of Ellipticine\nDerivatives","volume":"186","author":"Favre","year":"1992","journal-title":"C. R. Seances Soc. Biol. Ses Fil."},{"key":"2026090707083559800_cit28","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202400502","article-title":"Dual-Targeted Novel Temozolomide\nNanocapsules Encapsulating siPKM2 Inhibit Aerobic Glycolysis to Sensitize\nGlioblastoma to Chemotherapy","volume":"36","author":"Zhang","year":"2024","journal-title":"Adv. Mater."},{"key":"2026090707083559800_cit29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2217\/cns.13.20","article-title":"Lipid Metabolism Emerges as a Promising\nTarget for Malignant Glioma Therapy","volume":"2","author":"Guo","year":"2013","journal-title":"CNS Oncol."},{"key":"2026090707083559800_cit30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.cmet.2014.01.019","article-title":"Cholesteryl\nEster Accumulation Induced by PTEN Loss\nand PI3K\/AKT Activation Underlies Human Prostate Cancer Aggressiveness","volume":"19","author":"Yue","year":"2014","journal-title":"Cell Metab."},{"key":"2026090707083559800_cit31","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijpharm.2006.07.046","article-title":"Synthetic nano-low density lipoprotein\nas targeted\ndrug delivery vehicle for glioblastoma multiforme","volume":"328","author":"Nikanjam","year":"2007","journal-title":"Int. J. Pharm."},{"key":"2026090707083559800_cit32","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1021\/acs.jmedchem.0c01704","article-title":"Reactive Oxygen\nSpecies (ROS)-Responsive Prodrugs, Probes, and Theranostic Prodrugs:\nApplications in the ROS-Related Diseases","volume":"64","author":"Wang","year":"2021","journal-title":"J.\nMed. Chem."},{"key":"2026090707083559800_cit33","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202202744","article-title":"Glutathione Pulse Therapy: Promote Spatiotemporal Delivery\nof Reduction-Sensitive Nanoparticles at the \u2033Cellular Level\u2033\nand Synergize PD-1 Blockade Therapy","volume":"9","author":"Dong","year":"2022","journal-title":"Adv. Sci."},{"key":"2026090707083559800_cit34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jconrel.2019.04.001","article-title":"Self-Facilitated ROS-Responsive Nanoassembly of Heterotypic\nDimer\nfor Synergistic Chemo-Photodynamic Therapy","volume":"302","author":"Luo","year":"2019","journal-title":"J. Controlled Release"},{"key":"2026090707083559800_cit35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114363","article-title":"Enzyme-Powered\nMicellar Nanoreactors Enable Tumor-Specific, Cascade-Amplified Prodrug\nActivation for Synergistic Oxidation-Chemo-Immunotherapy","volume":"389","author":"Li","year":"2026","journal-title":"J. Controlled Release"},{"key":"2026090707083559800_cit36","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201706964","article-title":"Therapeutic Vesicular\nNanoreactors with Tumor-Specific Activation and Self-Destruction for\nSynergistic Tumor Ablation","volume":"56","author":"Li","year":"2017","journal-title":"Angew. Chem., Int.\nEd."},{"key":"2026090707083559800_cit37","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1021\/acsnano.7b08219","article-title":"Light-Activatable Red\nBlood Cell Membrane-Camouflaged Dimeric Prodrug\nNanoparticles for Synergistic Photodynamic\/Chemotherapy","volume":"12","author":"Pei","year":"2018","journal-title":"ACS Nano"},{"key":"2026090707083559800_cit38","doi-asserted-by":"publisher","first-page":"12086","DOI":"10.1021\/acsnano.1c03416","article-title":"Visible-Light-Triggered\nProdrug Nanoparticles Combine\nChemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade\nCancer Immunotherapy","volume":"15","author":"Choi","year":"2021","journal-title":"ACS Nano"},{"key":"2026090707083559800_cit39","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s12274-019-2330-y","article-title":"Photodynamic Therapy-Triggered On-Demand\nDrug Release from ROS-Responsive Core-Cross-Linked Micelles toward\nSynergistic Anti-Cancer Treatment","volume":"12","author":"Li","year":"2019","journal-title":"Nano Res."},{"key":"2026090707083559800_cit40","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2023.121210","article-title":"Formulation of DOX-Dimer\nwith Bi-Functionalized Chitooligosaccharide\nfor Tumor-Specific Self-Boosted Drug Release and Synergistic Chemo\/Chemodynamic\nTherapy","volume":"320","author":"Xie","year":"2023","journal-title":"Carbohydr. Polym."},{"key":"2026090707083559800_cit41","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S1081-1206(10)61024-1","article-title":"Polysorbate\n80 in Medical\nProducts and Nonimmunologic Anaphylactoid Reactions","volume":"95","author":"Coors","year":"2005","journal-title":"Ann. Allergy, Asthma, Immunol."},{"key":"2026090707083559800_cit42","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jconrel.2020.08.062","article-title":"Photosensitizer-Stabilized\nSelf-Assembling\nNanoparticles Potentiate Chemo\/Photodynamic Efficacy of Patient-Derived\nMelanoma","volume":"328","author":"Huang","year":"2020","journal-title":"J. Controlled Release"},{"key":"2026090707083559800_cit43","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ajps.2019.05.002","article-title":"In Situ\nApolipoprotein E-Enriched Corona Guides Dihydroartemisinin-Decorating\nNanoparticles towards LDLr-Mediated Tumor-Homing Chemotherapy","volume":"15","author":"Li","year":"2020","journal-title":"Asian J. Pharm. Sci."},{"key":"2026090707083559800_cit44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/sj.cdd.4402269","article-title":"Molecular Characteristics\nof Immunogenic\nCancer Cell Death","volume":"15","author":"Tesniere","year":"2008","journal-title":"Cell Death Differ."},{"key":"2026090707083559800_cit45","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/ijc.23538","article-title":"Disparity between Prostate Tumor Interior versus\nPeripheral Vasculature in Response to Verteporfin-Mediated Vascular-Targeting\nTherapy","volume":"123","author":"Chen","year":"2008","journal-title":"Int. J. Cancer"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00317","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/9\/4579\/66305109\/acs.molpharmaceut.6c00317.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/9\/4579\/66305109\/acs.molpharmaceut.6c00317.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:30:15Z","timestamp":1788780615000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/9\/4579\/5235363\/Low-Density-Lipoprotein-Mimetic-Nanoparticles"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":45,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,7,28]]},"published-print":{"date-parts":[[2026,9,7]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00317","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]}}}